VitalTransformation

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two guests on reshoring, generic pricing, supply chain resilience, and medicine access: - Patrick Kelly, Chief Advocacy Officer at HDA - Healthcare Distribution Alliance (@HDAconnect) - John Murphy III (@JAMurphy_III), President and CEO at Association for Accessible Medicines (@AccessibleMeds) Watch the full episode here: omny.fm/shows/vital-he… #VitalHealthPodcast #Generics #Reshoring #HealthPolicy #MedicineSupplyChain

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two guests on tariffs, generic pricing, reshoring, supply chain risk, and medicine access: - Patrick Kelly, Chief Advocacy Officer at HDA - Healthcare Distribution Alliance (@HDAconnect) - John Murphy III (@JAMurphy_III), President and CEO at Association for Accessible Medicines (@AccessibleMeds) Watch the full episode here: omny.fm/shows/vital-he… #VitalHealthPodcast #Generics #Tariffs #HealthPolicy #MedicineSupplyChain

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two guests on biosimilar competition, insurer incentives, generic pricing, tariffs, reshoring, and medicine access: - Patrick Kelly, Chief Advocacy Officer at HDA - Healthcare Distribution Alliance (@HDAconnect) - John Murphy III (@JAMurphy_III), President and CEO at Association for Accessible Medicines (@AccessibleMeds) Watch the full episode here: omny.fm/shows/vital-he… #VitalHealthPodcast #Biosimilars #Generics #HealthPolicy #MedicineAccess

Biosimilars are supposed to give patients more lower-cost alternatives to expensive biologic medicines. But John Murphy warns that when insurers and PBMs make their own private-label biosimilars and give those products preferred placement, other biosimilar makers may have less reason to invest in the market. In this best-of edition of the Vital Health Podcast, we revisit conversations Duane Schulthess (@DuaneSchulthess) had with Patrick Kelly, Chief Advocacy Officer at the Healthcare Distribution Alliance (@HDAconnect), and John Murphy (@JAMurphy_III), President and CEO of the Association for Accessible Medicines (@accessiblemeds), on supply chain risk, generic shortages, biosimilar competition, IRA redesign, insurer incentives, and patient access. Listen to the full episode here: omny.fm/shows/vital-he… #VitalHealthPodcast #IRA #MFN #Biotechnology

Generic medicines account for 90% of prescriptions in the United States. Yet, many older generics and sterile injectables are priced so low that manufacturers have limited room to reinvest, add redundancy, or absorb new cost pressures. In this best-of edition of the Vital Health Podcast, we revisit two conversations Duane Schulthess (@DuaneSchulthess) had with Patrick Kelly, Chief Advocacy Officer at the Healthcare Distribution Alliance (@HDAconnect), and John Murphy (@JAMurphy_III), President and CEO of the Association for Accessible Medicines (@accessiblemeds), on generic pricing, shortages, tariffs, reshoring, biosimilars, and the policy pressures shaping medicine access. Listen to the full episode here: omny.fm/shows/vital-he… #VitalHealthPodcast #IRA #MFN #Biotechnology

In this best-of edition of the Vital Health Podcast, we revisit two conversations Duane Schulthess (@DuaneSchulthess) has with experts on the future of generic medicines, drug shortages, and supply chain risk in the United States. - Patrick Kelly: Chief Advocacy Officer, Healthcare Distribution Alliance (@HDAconnect) - John Murphy (@JAMurphy_III): President and CEO, Association for Accessible Medicines (@accessiblemeds) Across these conversations, they discuss how low prices, thin margins, supply chain disruption, reshoring pressure, biosimilar market dynamics, insurance design, and federal pricing policy shape access to generic and biosimilar medicines. Listen to the full episode here: omny.fm/shows/vital-he… #VitalHealthPodcast #IRA #MFN #Biotechnology

Better Science, Better Health is Vital Transformation’s educational channel for making complex healthcare research and policy easier to follow. The channel was created to help translate research, regulation, evidence, and health policy topics into clear, accessible discussions for the broader healthcare community. From drug value and access to regulatory decision-making and real-world evidence, Gwen O’Loughlin and Petra Naster (@PetraNaster) break down the issues shaping healthcare today. Follow the channel on YouTube: @BSBHbyBT" target="_blank" rel="nofollow noopener">youtube.com/@BSBHbyBT #BSBHbyVT #HealthPolicy #Healthcare #HealthEconomics @BSBHbyVT

In this episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Christopher Locher, CEO at Versatope Therapeutics (@VersatopeRx), about the founding of Versatope, universal flu vaccine development, infectious disease financing, nanoparticle vaccine technology, population health, and antimicrobial resistance, when microbes stop responding to medicines. Watch the full episode here: youtube.com/watch?v=VOTkTr… Learn more about Versatope Therapeutics here: versatope.com #VitalHealthPodcast #Vaccines #Influenza #Biotech #AntimicrobialResistance #HealthPolicy

In this episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Christopher Locher, CEO at Versatope Therapeutics (@VersatopeRx), about National Institutes of Health (NIH) funding, studies in people, Food and Drug Administration (FDA) allowance, canceled research contracts, and grant cuts affecting small biotechnology companies. - Watch the full episode here: youtube.com/watch?v=VOTkTr… - Read the referenced STAT article here: statnews.com/2026/03/17/nih… #VitalHealthPodcast #NIH #ClinicalResearch #Vaccines #Biotech #HealthPolicy

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Christopher Locher, CEO at Versatope Therapeutics (@VersatopeRx), about vaccine financing, small biotechnology companies, private capital, the Inflation Reduction Act, and the market for biologics and vaccines. Watch the full episode here: youtube.com/watch?v=VOTkTr… #VitalHealthPodcast #Vaccines #Biotech #HealthPolicy #Biopharma #IRA

In this episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Christopher Locher, Chief Executive Officer at Versatope Therapeutics (@VersatopeRx), about childhood vaccination policy, U.S. and European immunization systems, school requirements, reviewing benefits and risks, and public trust in vaccine guidance. Watch the full episode here: youtube.com/watch?v=VOTkTr… #VitalHealthPodcast #Vaccines #Immunization #PublicHealth #HealthPolicy

In our latest episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Christopher Locher, Chief Executive Officer at Versatope Therapeutics (@VersatopeRx), about the current landscape for vaccine manufacturers and innovators. Their conversation covers vaccine platform development, financing challenges for infectious disease companies, policy and regulatory uncertainty, the public health implications of changes to childhood immunization schedules, and the steps needed to rebuild trust in vaccination. Watch the full episode here: youtube.com/watch?v=VOTkTr…

Better Science, Better Health (@BSBHbyVT) is Vital Transformation's channel for making complex healthcare topics easier to follow. Through podcasts, articles, and other content, Gwen O'Loughlin and Petra Naster (@PetraNaster) help translate research, regulation, and evidence into clearer explanations for a broader healthcare audience. See the refreshed website here: bettersciencebetterhealth.com #BSBHbyVT #MFN #HealthPolicy

New on Better Science, Better Health: Gwen O'Loughlin and Petra Naster (@PetraNaster) take a closer look at how the prisoner's dilemma helps explain drug pricing policy. In this first episode, they unpack MFN, competition, innovation, and the tradeoffs that can shape whether medicines reach patients in clear, practical language. Watch here: youtube.com/watch?v=qrPJqc… @BSBHbyVT #HealthPolicy #IRA #MFN #DrugPricing

If you are interested in clear conversations around healthcare research and policy, Better Science Better Health (@BSBHbyVT) is worth following. Created by Vital Transformation (@VitalTransform), the channel features Gwen O'Loughlin and Petra Naster (@PetraNaster) translating complex topics into accessible discussion, with a focus on helping more people engage with the ideas shaping healthcare today. See the YouTube channel here: @BSBHbyBT" target="_blank" rel="nofollow noopener">youtube.com/@BSBHbyBT #BSBHbyVT #HealthPolicy #Biotechnology #MFN #DrugPricing

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Melanie Whittington (@mel_whittington), Managing Director and Head of the Leerink Center for Pharmacoeconomics, about health economic modeling, medicine pricing debates, risks to oncology innovation, value assessment limits, and generics and biosimilars. - Watch the full episode here: youtu.be/5yjUIaI_Bhs - Read the report from Fierce Pharma: fiercepharma.com/special-report… #VitalHealthPodcast #HealthEconomics #HealthPolicy #Biopharma #Generics #Biosimilars Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp.

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Melanie Whittington (@mel_whittington), Managing Director and Head of the Leerink Center for Pharmacoeconomics, about health economic modeling, medicine pricing debates, risks to oncology innovation, the limits of conventional cost-effectiveness frameworks, and the role of transparency. Watch the full episode here: youtu.be/5yjUIaI_Bhs #VitalHealthPodcast #HealthEconomics #HealthPolicy #Biopharma #Oncology Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp.

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Melanie Whittington (@mel_whittington), Managing Director and Head of the Leerink Center for Pharmacoeconomics, to explain why some medicines are priced higher early, then decline sharply after exclusivity ends, while long-term patient and health system benefits continue. Watch the full episode here: youtu.be/5yjUIaI_Bhs #VitalHealthPodcast #HealthEconomics #HealthPolicy #Biopharma #DrugPricing Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp.

High launch prices for medicines are presented as a temporary reward for the small share of risky drug development efforts that succeed. In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Melanie Whittington (@mel_whittington), Managing Director and Head of the Leerink Center for Pharmacoeconomics, about health economic modeling, how medicines are priced, pricing policy, and price transparency. Watch the full episode here: youtu.be/5yjUIaI_Bhs #VitalHealthPodcast #HealthEconomics #HealthPolicy #Biopharma #DrugPricing Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp.

In our latest episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Melanie Whittington (@mel_whittington), Managing Director and Head of the Leerink Center for Pharmacoeconomics. They examine how health economic modeling can more accurately reflect real-world market dynamics, the rising pressure behind IRA and MFN drug pricing, the risks to oncology innovation, the limits of conventional cost-effectiveness frameworks, plus the role of transparency and clearer communication of long-term value in sustaining a healthy innovation ecosystem. Watch the full episode here: youtu.be/5yjUIaI_Bhs #VitalHealthPodcast #HealthEconomics #HealthPolicy #Biopharma #DrugPricing Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp.